Developments in predictive biomarkers for hepatocellular carcinoma therapy.

Area of Science:

• Hepatology
• Oncology
• Biomarker Discovery

Background:

• Hepatocellular carcinoma (HCC) is a prevalent liver cancer with significant global mortality.
• Curative treatments are limited, necessitating effective therapies for intermediate and advanced stages.
• Accurate biomarkers are urgently needed to guide treatment selection for HCC patients.

Purpose of the Study:

• To review existing biological markers for predicting treatment efficacy in HCC.
• To introduce a novel biomarker with future potential for HCC management.
• To explore strategies for overcoming challenges in assessing tumor heterogeneity.

Main Methods:

• Literature review of biological markers for HCC treatment efficacy.
• Discussion of a novel biomarker for HCC prognosis and response.
• Exploration of multi-omics and radiomics integration for tumor characterization.

Main Results:

• Current biomarkers have limitations in predicting HCC treatment outcomes.
• Tumor heterogeneity in HCC impacts prognosis and treatment response.
• Multi-omics and radiomics integration show promise in evaluating tumor heterogeneity.

Conclusions:

• Effective biomarkers are essential for personalized HCC treatment.
• Addressing tumor heterogeneity is key to improving HCC patient outcomes.
• Integrating multi-omics with radiomics represents a promising future direction for HCC biomarker discovery and treatment selection.